α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
α-synuclein aggregation assay - Innoprot Parkinson's Disease Models
.jpg)
Parkinsons Disease - Neurobiology and Aetiology - Neurotorium
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery
IJMS, Free Full-Text
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Cellular models of alpha‐synuclein toxicity and aggregation - Delenclos - 2019 - Journal of Neurochemistry - Wiley Online Library
Frontiers Modeling Parkinson's Disease With the Alpha-Synuclein Protein
Alpha Synuclein Assay
Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy
α-Synuclein Aggregation in Treatment of Parkinson's Disease
Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson's Disease
Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease
de
por adulto (o preço varia de acordo com o tamanho do grupo)
